Aegerion Pharmaceuticals

Aegerion Pharmaceuticals is a biopharmaceutical company that specializes in developing and commercializing innovative therapies for patients with rare diseases. The company was founded in 2005 and has a focus on developing treatments for rare genetic lipid disorders, including homozygous familial hypercholesterolemia (HoFH) and familial chylomicronemia syndrome (FCS). Aegerion has developed drugs such as lomitapide (Juxtapid) for the treatment of HoFH and has been involved in research and development for other rare diseases related to lipid metabolism.